The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.

Method of producing an activated clostridial neurotoxin. Composition comprising an activated clostridial neurotoxin. Method of treatment using a composition comprising an activated clostridial neurotoxin.

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and tor increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.

Polyethylene glycol modified human chorionic gonadotropin (hCG), preparations thereof, compositions thereof, and methods of preparation and use thereof are described.

The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or —CR.sub.0—, where R.sub.0 is hydrogen, C.sub.1-C.sub.6 linear or branched chain alkyl, etc., Z is —CR.sub.e—, or, —N—, where R.sub.e is hydrogen, C.sub.1-C.sub.6 linear or branched chain alkyl, etc.; R.sub.1 is hydrogen, C.sub.1-C.sub.6 linear or branched chain alkyl, etc.; R.sub.2 are independently hydrogen or C.sub.1-C.sub.6 linear or branched chain alkyl; R.sub.3 and R.sub.4 are independently hydrogen, C.sub.1C.sub.6 linear or branched chain alkyl, etc.; R.sub.5 and R.sub.6 are independently hydrogen or C.sub.1-C.sub.6 linear or branched chain alkyl, etc.; R.sub.8 is hydrogen, C.sub.1-C.sub.6 linear or branched chain alkyl, etc.; R.sub.9 and R.sub.10 are independently hydrogen or C.sub.1-C.sub.6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH.sub.2).sub.q—, —(CHR.sub.s).sub.q—, or —(CR.sub.sR.sub.t).sub.q—, where R.sub.s and R.sub.t are independently C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where .sub.q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

##STR00001##

The present disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.

The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

Disclosed is a composition, which comprises Hordeum vulgare extract as an active ingredient and is effective at promoting longitudinal bone growth.

This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.